Beta-Blockers with Intrinsic Sympathomimetic Activity (ISA)
The beta-blockers with intrinsic sympathomimetic activity (partial agonist activity) are acebutolol, penbutolol, pindolol, labetalol, and carvedilol 1, 2, 3.
Specific Agents with ISA
Based on the most recent ACC/AHA hypertension guidelines from 2017/2018, the following beta-blockers possess ISA:
Beta-1 Selective with ISA:
- Acebutolol (200-800 mg twice daily)
Non-Cardioselective with ISA:
- Penbutolol (10-40 mg once daily)
- Pindolol (2.5-7.5 mg three times daily or 10-60 mg twice daily)
Combined Alpha- and Beta-Receptor Blockers with ISA:
- Labetalol (200-800 mg twice daily)
- Carvedilol (12.5-50 mg twice daily or 20-80 mg once daily for phosphate formulation)
Critical Clinical Caveat
Beta-blockers with ISA should generally be avoided, especially in patients with ischemic heart disease (IHD) or heart failure 1, 2, 3. The 2017 ACC/AHA hypertension guidelines explicitly state to "generally avoid, especially in patients with IHD or HF" for agents with ISA 1, 3.
This recommendation is reinforced by multiple ACC/AHA guidelines for unstable angina/NSTEMI management, which consistently state: "Beta blockers without intrinsic sympathomimetic activity are preferred" 4, 5, 4, 5. The rationale is that ISA may provide modest beta-receptor stimulation, which can be deleterious in conditions requiring complete beta-blockade such as acute coronary syndromes and heart failure.
Mechanism of ISA
Beta-blockers with ISA act as partial agonists at beta-adrenergic receptors. They can induce modest increases in beta-receptor-stimulated activity (such as heart rate and contractility) while simultaneously blocking the effects of endogenous catecholamines 6, 7. This dual action results in:
- Less reduction in resting heart rate compared to pure antagonists
- Maintained cardiac output at rest
- Potential for inadequate heart rate reduction during stress or exercise
When ISA Becomes Problematic
The partial agonist activity is particularly concerning in:
- Acute coronary syndromes: Where maximal reduction in myocardial oxygen demand is critical
- Heart failure: Where any beta-receptor stimulation may worsen outcomes (xamoterol and bucindolol trials showed increased mortality) 8, 9
- Post-myocardial infarction: Where complete beta-blockade provides mortality benefit
Preferred Alternatives
For cardiovascular indications, beta-blockers without ISA are preferred:
- Metoprolol
- Atenolol
- Propranolol
- Nadolol
- Bisoprolol
- Nebivolol (has vasodilatory properties via nitric oxide, not ISA)
Note that while labetalol and carvedilol are listed as having "partial agonist activity" in guideline tables 4, 5, 10, carvedilol is specifically recommended for heart failure with reduced ejection fraction and has proven mortality benefit, distinguishing it from other ISA agents.